NYSE:DVAHealthcare
A Look at DaVita's Valuation Following Q3 Profit Drop and Clinical Innovation Push
DaVita (DVA) just rolled out its third quarter report, showing profit and margin declines largely tied to lower treatment volumes following a tough flu season, Hurricane Helene, and a cyber incident. Management emphasized ongoing cost control and investment in clinical innovation. The company also announced new research initiatives at the American Society of Nephrology’s Kidney Week.
See our latest analysis for DaVita.
Despite a tough run in 2025, marked by weather disruptions, a flu surge,...